抗血小板联合抗凝治疗心源性脑梗死的临床观察

Antiplatelet plus Anticoagulant Therapy for Cardiogenic Cerebral Infarction: Clinical Obseration

目的:探讨在抗血小板治疗的基础上联合抗凝治疗对心源性脑梗死患者的临床效果。方法:将70例心源性脑梗死患者按入院时间顺序随机分为联合组与单独组各35例,单独组患者仅采用抗血小板治疗,联合组患者在此基础上同时给予抗凝治疗。对比观察2组患者的治疗效果和治疗前后神经功能缺损评分、日常生活能力评定量表指数变化情况。结果:联合组患者的总有效率明显高于单独组[80.00%(28/35)相比60.00%(21/35)],差异有统计学意义(P<0.05);治疗30、90 d后,联合组患者的神经功能缺损评分、日常生活能力评定量表指数均优于单独组,差异有统计学意义(P<0.05)。结论:心源性脑梗死患者在抗血小板治疗的基础上联合抗凝治疗,效果显著,值得临床推广。

OBJECTIVE： To evalute the clinical efficacy of antiplatelet plus anticoagulant therapy in treating patients with cardiogenic cerebral infarction. METHODS： 70 patients with cardiac cerebral infarction were randomly assigned to either antiplatelet plus anticoagulant group or antiplatelet alone group of 35 cases each. The two groups were compared with regard to curative efficacy,NIHSS score（ nerve function defect score） and BI index（ activity of daily life） etc. RESULTS： The total effective rate in the antiplatelet plus anticoagulant group was significantly higher than in the antiplatelet alone group[80. 00%（ 28 /35） vs. 60. 00%（ 21 /35）,P〈0. 05） ]; at 30 and 90 days,the NIHSS score and BI index in the antiplatelet plus anticoagulant group was significantly better than in the antiplatelet alone group（ P〈0. 05）. CONCLUSIONS： Treatment of cardiac cerebral infarction using antiplatelet plus anticoagulant therapy resulted in excellent efficacy,which thus is worthy of clinical promotion.